NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$140.92 +1.01 (+0.72 %)
(As of 05/23/2019 09:13 AM ET)
Previous Close$139.91
Today's Range$139.8392 - $141.59
52-Week Range$113.52 - $184.00
Volume647,206 shs
Average Volume445,697 shs
Market Capitalization$7.98 billion
P/E Ratio11.51
Dividend YieldN/A
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:JAZZ



Sales & Book Value

Annual Sales$1.89 billion
Cash Flow$16.8766 per share
Book Value$48.19 per share


Net Income$447.10 million


Market Cap$7.98 billion
Next Earnings Date8/6/2019 (Estimated)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) released its quarterly earnings data on Tuesday, May, 7th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.83 by $0.44. The specialty pharmaceutical company had revenue of $508.19 million for the quarter, compared to the consensus estimate of $466.55 million. Jazz Pharmaceuticals had a net margin of 24.88% and a return on equity of 27.35%. The company's revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.98 earnings per share. View Jazz Pharmaceuticals' Earnings History.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Jazz Pharmaceuticals.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY19 earnings guidance on Tuesday, May, 7th. The company provided EPS guidance of $14.30-15.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.61. The company issued revenue guidance of $2.05-2.13 billion, compared to the consensus revenue estimate of $2.07 billion.Jazz Pharmaceuticals also updated its FY 2019 guidance to $14.30-15.00 EPS.

What price target have analysts set for JAZZ?

17 analysts have issued 1-year price targets for Jazz Pharmaceuticals' stock. Their predictions range from $135.00 to $210.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $183.9375 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals.

What is the consensus analysts' recommendation for Jazz Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals.

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We’ve long highlighted how conservative EPS guidance has been since JAZZ missed analyst estimates repeatedly through 2016-17, and it’s worked, with five straight beats of increasing magnitude. Jazz didn’t raise despite the 1Q beat, but our 2019 EPS is now at $15.21 vs. guidance of $14.30-15.00. Our view that the Street won’t give much credit for Xyrem- driven beats given lack of clarity beyond 2022 is largely unchanged for now. Further, recent quarterly beats have included outliers, like an abnormally low tax-rate in 3Q-4Q18, or large Erwinaze upside this quarter (presumably a one-off), or head-scratchers like the surprisingly strong Xyrem this quarter. Xyrem sales of $368M easily beat consensus by $14M, but the 5% YoY volume growth and 7% price hike would have yielded an approximately in-line $356M number." (5/10/2019)
  • 2. According to Zacks Investment Research, "Jazz’s key drug, Xyrem, witnessed improved volume trends in 2018 on the back of awareness efforts. The label expansion of Xyrem in pediatric patients is likely to boost Jazz’s top line. Management seems confident that Xyrem will continue to generate volume growth in 2019. Meanwhile, Jazz’s lead pipeline candidate, solriamfetol complements the sleep disorder portfolio and successful development will offset decline in Xyrem’s sales following patent expiry in 2023. Jazz’s leukemia drug, Vyxeos, also witnessed strong growth in late 2018. Launch in Europe will also boost sales in 2019. However, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity. These supply challenges are expected to continue in 2019. Los estimates have been stable ahead of the company’s Q1 earnings release. The company has a positive record of earnings surprises in the recent quarters." (5/6/2019)
  • 3. Mizuho analysts commented, "We raise our PT to $147 from $137 based on two recent positive catalysts: approval of Sunosi (solriamfetol for excessive sleepiness), and last night’s positive data in the Phase III trial of JZP-258 (low sodium Xyrem). Both these events were largely expected and we reiterate our Neutral rating on JAZZ." (3/27/2019)
  • 4. Cantor Fitzgerald analysts commented, "We have an Overweight rating and a 12-month price target of $185 on JAZZ shares. We believe that the sleep franchise durability remains underappreciated and that the company has an interesting hemo/oncology business that could drive the next leg of growth and evolution for JAZZ. We believe that data readouts in 2019 and upward earnings revisions in both segments of the business will drive upside to JAZZ’s current share price. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $185 price target." (3/26/2019)

Has Jazz Pharmaceuticals been receiving favorable news coverage?

Media stories about JAZZ stock have been trending very negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jazz Pharmaceuticals earned a news impact score of -3.8 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Netflix (NFLX), Celgene (CELG), Alibaba Group (BABA), Allergan (AGN), Micron Technology (MU), Baidu (BIDU), Biogen (BIIB) and Alphabet (GOOG).

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the folowing people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Matthew P. Young, Exec. VP & CFO (Age 50)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)
  • Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)
  • Mr. Paul Treacy, Sr. VP of Technical Operations (Age 58)

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.16%), FMR LLC (6.02%), JPMorgan Chase & Co. (3.98%), Renaissance Technologies LLC (3.52%), Boston Partners (2.30%) and LSV Asset Management (1.76%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.

Which institutional investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, FMR LLC, Voya Investment Management LLC, Viking Global Investors LP, Scout Investments Inc., Carillon Tower Advisers Inc., Morgan Stanley and Systematic Financial Management LP. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.

Which institutional investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., Wedge Capital Management L L P NC, LSV Asset Management, AQR Capital Management LLC, Clark Capital Management Group Inc., Goldman Sachs Group Inc. and AJO LP. View Insider Buying and Selling for Jazz Pharmaceuticals.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $140.92.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $7.98 billion and generates $1.89 billion in revenue each year. The specialty pharmaceutical company earns $447.10 million in net income (profit) each year or $12.24 on an earnings per share basis. Jazz Pharmaceuticals employs 1,360 workers across the globe.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]

MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  872 (Vote Outperform)
Underperform Votes:  354 (Vote Underperform)
Total Votes:  1,226
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/23/2019 by Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel